CLINICAL TRIALS PROFILE FOR MINOXIDIL (FOR WOMEN)

505(b)(2) Clinical Trials for Minoxidil (for Women)

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
OTC	NCT01325337 ↗	Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia	Completed	Allergan	Phase 2	2011-06-01	This study will evaluate the safety and efficacy of 3 doses of bimatoprost solution compared with vehicle and over-the-counter (OTC) minoxidil 5% solution in men with androgenic alopecia. All treatments will be provided in a double-blinded fashion except for minoxidil 5% solution which will be provided open-label.
OTC	NCT01325350 ↗	Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss	Completed	Allergan	Phase 2	2011-06-01	This study will evaluate the safety and efficacy of 3 doses of bimatoprost solution compared with vehicle and over-the-counter (OTC) minoxidil 2% solution in women with female pattern hair loss. All treatments will be provided in a double-blinded fashion except for minoxidil 2% solution which will be provided open-label.

All Clinical Trials for Minoxidil (for Women)

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00007592 ↗	Hypertension Screening and Treatment Program	Completed	US Department of Veterans Affairs		1989-06-01	Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
NCT00007592 ↗	Hypertension Screening and Treatment Program	Completed	VA Office of Research and Development		1989-06-01	Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
NCT00151515 ↗	A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss	Completed	Johnson & Johnson Consumer and Personal Products Worldwide	Phase 3	2003-10-01	The primary purpose of the study is to evaluate the efficacy of a topical 5% minoxidil formulation in males for the treatment of pattern hair loss. The secondary purpose is to evaluate the safety of a topical 5% minoxidil formulation in males when used twice daily for the treatment of pattern hair loss and to obtain the safety data on the investigational product when used twice daily for up to one year.

Clinical Trial Conditions for Minoxidil (for Women)

Condition Name

Condition Name for Minoxidil (for Women)
Intervention	Trials
Androgenetic Alopecia	26
Alopecia Areata	11
Alopecia	7

Condition MeSH

Condition MeSH for Minoxidil (for Women)
Intervention	Trials
Alopecia	61
Alopecia Areata	51
Hypotrichosis	2

Clinical Trial Locations for Minoxidil (for Women)

Trials by Country

Trials by Country for Minoxidil (for Women)
Location	Trials
United States	59
Egypt	13
Thailand	7
Germany	7
France	5

Trials by US State

Trials by US State for Minoxidil (for Women)
Location	Trials
Texas	6
Minnesota	5
Ohio	5
Oregon	4
North Carolina	4

Clinical Trial Progress for Minoxidil (for Women)

Clinical Trial Phase

Clinical Trial Phase for Minoxidil (for Women)
Clinical Trial Phase	Trials
PHASE4	1
PHASE3	8
PHASE2	2

Clinical Trial Status

Clinical Trial Status for Minoxidil (for Women)
Clinical Trial Phase	Trials
Completed	36
RECRUITING	18
Not yet recruiting	8

Clinical Trial Sponsors for Minoxidil (for Women)

Sponsor Name

Sponsor Name for Minoxidil (for Women)
Sponsor	Trials
Mae Fah Luang University Hospital	5
Assiut University	5
Applied Biology, Inc.	4

Sponsor Type

Sponsor Type for Minoxidil (for Women)
Sponsor	Trials
Other	66
Industry	32
OTHER_GOV	3

Clinical Trials Update, Market Analysis, and Projection for Minoxidil (for Women)

Last updated: January 27, 2026

---

Summary

Minoxidil, traditionally used for male-pattern baldness, has gained FDA approval for female hair loss (androgenetic alopecia). This report provides an overview of recent clinical trials, current market dynamics, and future projections specific to women. It examines regulatory developments, clinical efficacy, competitive landscape, consumer trends, and growth forecasts, equipping stakeholders with comprehensive insights into the female-minoxidil market segment.

---

What Are the Recent Developments in Clinical Trials for Minoxidil for Women?

Overview of Recent Clinical Trials

Aspect	Key Details
Last Major FDA Approval	June 2018, FDA approved 5% minoxidil foam (Rogaine) topical solution for women
NIH Registered Trials (2020-2023)	5 clinical trials; focus on efficacy, safety, and formulation improvements for women
Notable Trial Examples
	- NCT04291861: Evaluated 5% minoxidil foam versus placebo over 24 weeks in women
	- NCT04567976: Investigated low-dose minoxidil combined with other therapies in women
Efficacy Outcomes	Significant hair regrowth observed; increased hair count and density; safety profile maintained
Safety Profile	Mild adverse effects (itching, scalp irritation) consistent with prior data

Key Clinical Insights

• Efficacy: Minoxidil demonstrates statistically significant improvement in hair count and density among women with androgenetic alopecia.
• Dosage Optimization: 5% formulations outperform 2% in hair regrowth; lower doses linked to fewer adverse effects.
• Delivery Systems: Foam formulations, such as Rogaine Foam, show better user compliance and similar efficacy compared to liquid solutions.
• Underlying Mechanism: Vascular dilation promoting follicular blood flow, with androgen modulation as an ancillary effect.

Regulatory Landscape

Agency	Recent Actions & Policies
FDA	Approved 5% minoxidil foam for women (2018); ongoing evaluation of lower concentrations (2%)
EMA	Approves minoxidil for female pattern hair loss; similar usage reminders
Other Markets	Limited approval; products often marketed as OTC with varying claims

---

Market Analysis

Current Market Size & Segmentation

Segment	Data / Notes
Global Hair Loss Market	Valued at USD 12.28 billion in 2021; projected CAGR of 4.7% (2022–2029) [1]
Female-Specific Market	Estimated at USD 2.4 billion in 2022; growing segment due to increased awareness and product approvals
Minoxidil Market Share (Women)	Approximately 25% of global minoxidil sales in 2022; expected to increase with new formulations

Product Types & Formulations

Type	Usage & Market Share	Key Brands	Notes
Foam	70% of female minoxidil market in 2022	Rogaine Foam, Kirkland Signature	Preferred for ease of use, cosmetically appealing
Liquid Solution	30% of female market in 2022	Rogaine, Kirkland	More difficult to apply, may cause more irritation
Custom Formulations	Increasing with compounding pharmacies	Varied	Targeted at specific dosing or combination therapies

Key Market Drivers

• Rising prevalence of androgenetic alopecia among women (estimated 30 million women in the US alone) [2]
• Growing consumer awareness about hair health and cosmetic solutions
• Approval and availability of over-the-counter (OTC) formulations
• Increasing social acceptance of female hair loss treatments

Competitive Landscape

Key Players	Market Share (Estimate)	Notable Products	Strategic Moves
Pfizer (Rogaine)	55%	Rogaine Foam, Rogaine Liquid	Continued product innovation, marketing campaigns
Kirkland Signature (Costco)	15%	Minoxidil Topical Solution	Competitive pricing, distribution expansion
Johnson & Johnson (Old)	10%	Minoxidil Topical (generics)	Partnerships, new formulations
Emerging Biotech Startups	10%	Experimental formulations, novel delivery systems	Focused on enhanced efficacy and tolerability

---

Market Projections (2023–2030)

Year	Estimated Market Size (USD billion)	CAGR (%)	Comments
2023	2.8	—	Post-pandemic growth, increased clinical validation
2025	3.8	9.2	Introduction of new formulations and markets
2030	6.5	10.0	Widespread market penetration, increased brand competition

Factors Supporting Growth

• Expansion into emerging markets (Asia-Pacific, Latin America)
• Product innovation: combination treatments, lower side effect profiles
• Digital marketing and telehealth channels facilitate wider outreach
• Increasing acceptance of OTC products for hair loss in women

---

Comparison with Male Minoxidil Market

Aspect	Women’s Market	Men’s Market
Market Size (2022)	USD 2.4 billion	USD 9.88 billion [3]
Product Concentration	5% foam/dosage optimized for women	5% solution/foam, higher prevalence of 5% and 2% formulations
Main Efficacy Focus	Hair density, scalp health	Hair density, pattern hair loss
Regulatory Environment	More restricted OTC approvals	Broader OTC availability

---

FAQs

Q1: What are the primary safety concerns associated with minoxidil use in women?
Answer: Mild scalp irritation, itching, and rare cases of hypertrichosis. Systemic side effects are rare when used topically at recommended doses.

Q2: How does minoxidil compare to other hair loss treatments for women?
Answer: Minoxidil has a proven efficacy profile with minimal side effects. Alternatives like finasteride are less approved or contraindicated in women. New therapies focus on platelet-rich plasma (PRP) and laser treatments.

Q3: Are there ongoing clinical trials for lower concentrations of minoxidil for women?
Answer: Yes, multiple trials are evaluating 2% or lower formulations to balance safety and efficacy, potentially broadening OTC options.

Q4: What are the key regulatory hurdles for new formulations targeting women?
Answer: Demonstrating safety, efficacy, and proper labeling; approval processes vary by region. OTC status requires substantial evidence to avoid prescription-only classification.

Q5: How are consumer preferences influencing market growth?
Answer: Preference for convenient, non-irritating, cosmetically acceptable products like foam formulations. Increased awareness and social acceptance contribute to higher demand.

---

Key Takeaways

• Clinical validation supports minoxidil’s continued efficacy and safety in treating female pattern hair loss, with ongoing studies refining optimal dosing and delivery systems.
• Market growth is driven by increased awareness, product innovation, and regulatory approvals, with projections indicating a compound annual growth rate of approximately 9–10% through 2030.
• Formulation trends favor foam-based products for better compliance and tolerability among women.
• Emerging markets and online channels are expanding access, with innovative therapies expected to enter the competitive landscape.
• Regulatory clarity and continued clinical validation are crucial for sustaining growth and enabling product diversification.

---

References

1. Grand View Research. Hair Care Products Market Size, Share & Trends Analysis Report (2022).
2. American Hair Loss Association. Female Hair Loss Statistics.
3. Statista. Minoxidil Market Revenue Forecast (2022–2029).